左氧氟沙星与抗结核药联合治疗结核分枝杆菌阳性复治肺结核的可行性研究

Feasibility Analysis on Levofloxacin Combined with Anti-tuberculosis in Treatment of Recurrent Bacterial Positive Tuberculosis

目的:探讨左氧氟沙星与抗肺结核药联合治疗结核分枝杆菌阳性复治肺结核的可行性方法:选择2013年1月—2016年6月在宜都市第一人民医院接受治疗的结核分枝杆菌阳性复治肺结核患者80例,按照随机数字表法分为对照组和观察组,每组各40例。对照组患者进行单纯抗结核药治疗,观察组患者则进行左氧氟沙星与抗结核药联合治疗。比较2组患者的临床疗效、痰结核菌检查结果及不良反应发生率。结果:治疗后,观察组患者病灶总吸收率、空洞总闭合率分别为92.50%(37/40)、90.00%(36/40),均明显高于对照组的65.00%(26/40)、62.50%(25/40),差异均有统计学意义(P<0.05)。治疗4、8个月,观察组痰结核菌转阴率均明显高于对照组,差异均有统计学意义(P<0.05);但随访1年,2组患者痰结核菌复阳率的差异无统计学意义(P>0.05)。2组患者不良反应发生率的差异无统计学意义(P>0.05)。结论:左氧氟沙星与抗结核药联合治疗结核分枝杆菌阳性复治肺结核的临床疗效显著,不良反应也较少。

OBJECTIVE：To investigate the feasibility of levofloxacin combined with anti-tuberculosis in treatment of recurrent bacterial positive tuberculosis. METHODS： 80 patients with recurrent bacterial positive tuberculosis admitted into the First People＇ s Hospital of Yidu from Jan. 2013 to Jun. 2016 were selected to be divided into observation group and control group via the random number table, with 40 cases in each. The control group were given single anti- tuberculosis, while the observation group were treated with levofloxacin combined with anti-tuberculosis. The clinical efficacy, results of sputum examination and incidence of adverse drug reactions. RESULTS： After treatment, the total lesions absorption rate and the total rate of cavity closure of observation group were respectively 92. 50% （37/40） and 90. 00% （36/40）, significantly higher than those of control group [ 65.00% （26/40） and 62. 50% （25/40） ], with statistically significant difference （ P 〈 0. 05 ）. After treatment of 4 months, 8 months, the negative conversion rate of sputum examination of observation group was significantly higher than that of control group, with statistically significant difference （P 〈 0. 05 ）. There was no statistically significant difference between two groups in the incidence of adverse drug reactions （P 〉 0. 05 ）. CONCLUSIONS： The clinical efficacy of levofloxacin combined with anti-tuberculosis in treatment of recurrent bacterial positive tuberculosis is significant with few adverse drug reactions.